Management of New-Onset Venous Thromboembolism and Nonvalvular Atrial Fibrillation

In this podcast, Isaac Nichols, PharmD, speaks about the appropriateness of direct oral anticoagulation prescribing for new-onset venous thromboembolism and nonvalvular atrial fibrillation, specifically the Xa inhibitors, rivaroxaban and apixaban. He presented on this topic at ASHP Midyear 2021.

Additional Resource:

• Nichols I, Gwartney J, Rappsilber L. Appropriateness of direct oral anticoagulant (DOAC) prescribing for new onset venous thromboembolism and non-valvular atrial fibrillation. Poster presented at: American Society of Health-System Pharmacists Midyear Clinical Meeting 2021. December 5-9; Virtual. https://www.eventscribe.net/2021/midyear/fsPopup.asp?efp=RVBQQUNXV0Y5NTcz%20&PosterID=445307%20&rnd=0.4920062&mode=posterinfo 

Isaac Nichols, PharmD, is a PGY1 pharmacy resident at Oklahoma State University Medical Center in Tulsa, Oklahoma.